Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$29.02 ▼ -0.02
(-0.07%)
MKT CAP: $516.9M • VOL: 159.3K
52W L $11 52W H $38
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
SRZN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.5M | $10.7M | $128.2M |
| YoY Revenue Growth % | -67.4% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.1M | -$25.5M | -$45.8M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$242.0M | -$63.6M | -$43.0M |
| EBITDA (Normalized) | -$42.0M | -$25.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$30.2M | -$17.6M | -$40.4M |
| Capital Expenditures (CapEx) | $128.0K | $26.0K | — |
| Free Cash Flow (FCF) | -$30.4M | -$17.7M | -$40.4M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $89.2M | $34.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$187.8M | -$21.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SRZN.